Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility

Endocrine-Related Cancer

Volumn 22, Issue 1, 2015, Pages 65-76

  Toledo, Rodrigo A ^a   Hatakana, Roxanne ^a   Lourenço, Delmar M ^a   Lindsey, Susan C ^b   Camacho, Cleber P ^b   Almeida, Marcio ^e   Lima, José V ^f   Sekiya, Tomoko ^a   Garralda, Elena ^d   Naslavsky, Michel S ^a   Yamamoto, Guilherme L ^a   Lazar, Monize ^a   Meirelles, Osorio ^g   Sobreira, Tiago J P ^c   Lebrao, Maria Lucia ^a   Duarte, Yeda A O ^a   Blangero, John ^e   Zatz, Mayana ^a   Cerutti, Janete M ^b   Maciel, Rui M B ^b   Toledo, Sergio P A ^a,b   more..

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c BRAZILIAN CENTER FOR RESEARCH IN ENERGY AND MATERIALS CNPEM   (Brazil)

^d Centro Integral Oncológico Clara Campal HM CIOCC   (Spain)

^e AT AND T LABS RESEARCH   (United States)

^f Santa Casa Hospital   (Brazil)

^g NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Genetics; Medullary thyroid carcinoma; MEN2; Multiple endocrine; Neoplasias; RET oncogene

Indexed keywords

DNA; PROTEIN RET; RET PROTEIN, HUMAN;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BRAZILIAN; CANCER SUSCEPTIBILITY; CENTRAL EUROPEAN; COHORT ANALYSIS; COMPUTER MODEL; COMPUTER PREDICTION; CONTROLLED STUDY; DATA BASE; EUROPEAN AMERICAN; EXOME; FAMILY HISTORY; GENE DISRUPTION; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENOME ANALYSIS; HUMAN; HYPERPARATHYROIDISM; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; MEXICAN; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA; NEXT GENERATION SEQUENCING; ONCOGENE RET; PHENOTYPIC VARIATION; PHEOCHROMOCYTOMA; POPULATION; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; UNNECESSARY PROCEDURE; CARCINOMA; CASE CONTROL STUDY; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; GERMLINE MUTATION; MALE; METABOLISM; MUTATION; THYROID TUMOR;

AGED; CARCINOMA, NEUROENDOCRINE; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GERM-LINE MUTATION; HUMANS; MALE; MUTATION; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS;

EID: 84923621759     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0491     Document Type: Article

References (42)

1. Berndt I, Reuter M, Saller B, Frank-Raue K, Groth P, Grussendorf M, Raue F, Ritter MM & Höppner W 1998 A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. Journal of Clinical Endocrinology and Metabolism 83 770-774. (doi:10.1210/jcem.83.3.4619)
2. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A et al. 2001 Guidelines for diagnosis and therapy of MEN type 1 and type 2. Journal of Clinical Endocrinology and Metabolism 86 5658-5671. (doi:10.1210/jcem.86.12.8070)
3. Brauer VF, Scholz GH, Neumann S, Lohmann T, Paschke R & Koch CA 2004 RET germline mutation in codon 791 in a family representing 3 generations from age 5 to age 70 years: should thyroidectomy be performed? Endocrine Practice 10 5-9. (doi:10.4158/EP.10.1.5)
4. Carlino MS, Kwan V, Miller DK, Saunders CA, Yip D, Nagrial AM, Tomlinson J, Grimmond SM, Scolyer RA, Kefford RF et al. 2014 New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma. Journal of Clinical Oncology (In Press). (doi:10.1200/JCO.2013.51.5783)
5. Carlomagno F, Guida T, Anaganti S, Vecchio G, Fusco A, Ryan AJ, Billaud M & Santoro M 2004 Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 23 6056-6063. (doi:10.1038/sj.onc.1207810)
6. Cerutti JM & Maciel RM 2013 An unusual genotype-phenotype correlation in MEN 2 patients: should screening for RET double germline mutations be performed to avoid misleading diagnosis and treatment? Clinical Endocrinology 79 591-592. (doi:10.1111/cen.12155)
7. Colombo-Benkmann M, Li Z, Riemann B, Hengst K, Herbst H, Keuser R, Gross U, Rondot S, Raue F, Senninger N et al. 2008 Characterization of the RET protooncogene transmembrane domain mutation S649L associated with nonaggressive medullary thyroid carcinoma. European Journal of Endocrinology 158 811-816. (doi:10.1530/EJE-07-0817)
8. Cosci B, Vivaldi A, Romei C, Gemignani F, Landi S, Ciampi R, Tacito A, Molinaro E, Agate L, Bottici V et al. 2011 In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer. Endocrine-Related Cancer 18 603-612. (doi:10.1530/ERC-11-0117)
9. Edery P, Lyonnet S, Mulligan LM, Pelet A, Dow E, Abel L, Holder S, Nihoul-Fékété C, Ponder BA & Munnich A 1994 Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature 367 378-380. (doi:10.1038/367378a0)
10. Eng C 2010 Mendelian genetics of rare - and not so rare - cancers. Annals of the New York Academy of Sciences 1214 70-82. (doi:10.1111/j.1749-6632.2010.05789.x)
11. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI et al. 1996 The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. Journal of the American Medical Association 276 1575-1579. (doi:10.1001/jama.1996.03540190047028)
12. Erlic Z, Hoffmann MM, Sullivan M, Franke G, Peczkowska M, Harsch I, Schott M, Gabbert HE, Valimäki M, Preuss SF et al. 2010 Pathogenicity of DNA variants and double mutations in multiple endocrine neoplasia type 2 and von Hippel-Lindau syndrome. Journal of Clinical Endocrinology and Metabolism 95 308-313. (doi:10.1210/jc.2009-1728)
13. Feldman GL, Edmonds MW, Ainsworth PJ, Schuffenecker I, Lenoir GM, Saxe AW, Talpos GB, Roberson J, Petrucelli N & Jackson CE 2000 Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG→ATG) mutation. Surgery 128 93-98. (doi:10.1067/msy.2000.107103)
14. Fitze G, Schierz M, Bredow J, Saeger HD, Roesner D & Schackert HK 2002 Various penetrance offamilial medullary thyroid carcinoma in patients with RET protooncogene codon 790/791 germline mutations. Annals of Surgery 236 570-575. (doi:10.1097/00000658-200211000-00006)
15. Fitze G, Saeger HD, Roesner D & Schackert HK 2004 Management of multiple endocrine neoplasia syndrome type 2 families in association with rare germline mutations of the RET proto-oncogene. Klinische Pädiatrie 216 270-276. (doi:10.1055/s-2004-44902)
16. Frank-Raue K, Machens A, Scheuba C, Niederle B, Dralle H, Raue F & German MEN2 Study Group 2008 Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791. Clinical Endocrinology(Oxford) 69 259-263. (doi:10.1111/j.1365-2265.2008.03215.x)
17. Frank-Raue K, Döhring J, Scheumann G, Rondot S, Lorenz A, Schulze E, Dralle H, Raue F & Leidig-Bruckner G 2010 New mutations in the RET protooncogene-L881V - associated with medullary thyroid carcinoma and -R770Q - in a patient with mixed medullar/follicular thyroid tumour. Experimental and Clinical Endocrinology & Diabetes 118 550-553. (doi:10.1055/s-0029-1241851)
18. Freudenberg-Hua Y, Jan Freudenberg J, Vacic V, Abhyankar A, Emde AK, Ben-Avraham D, Barzilai N, Oschwald D, Christen E, Koppel J et al. 2014 Disease variants in genomes of 44 centenarians. Molecular Genetics & Genomic Medicine 2 438-450. (doi:10.1002/mgg3.86)
19. Gimm O, Niederle BE, Weber T, Bockhorn M, Ukkat J, Brauckhoff M, Thanh PN, Frilling A, Klar E, Niederle B et al. 2002 RET proto-oncogene mutations affecting codon 790/791: a mild form of multiple endocrine neoplasia type 2A syndrome? Surgery 132 952-959. (doi:10.1067/msy.2002.128559)
20. Hyndman BD, Gujral TS, Krieger JR, Cockburn JG & Mulligan LM 2013 Multiple functional effects of RET kinase domain sequence variants in Hirschsprung disease. Human Mutation 34 132-142. (doi:10.1002/humu.22170)
21. Jindrichova S, Vcelak J, Vlcek P, Neradilova M, Nemec J & Bendlova B 2004 Screening of six risk exons of the RET proto-oncogene in families with medullary thyroid carcinoma in the Czech Republic. Journal of Endocrinology 83 257-265. (doi:10.1677/joe.1.05838)
22. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M et al. 2009 Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19 565-612. (doi:10.1089/thy.2008.0403)
23. Krieger E, Joo K, Lee J, Lee J, Raman S, Thompson J, Tyka M, Baker D & Karplus K 2009 Improving physical realism, stereochemistry, and side-chain accuracy in homology modeling: four approaches that performed well in CASP8. Proteins 77 (Suppl 9) 114-122. (doi:10.1002/prot.22570)
24. Li Y, Willer CJ, Ding J, Scheet P & Abecasis GR 2010 MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genetic Epidemiology 34 816-834. (doi:10.1002/gepi.20533)
25. Margraf RL, Crockett DK, Krautscheid PM, Seamons R, Calderon FR, Wittwer CT & Mao R 2009 Multiple endocrine neoplasia type 2 RET protooncogene database: repository of MEN2-associated RET sequence variation and reference for genotype/phenotype correlations. Human Mutation 30 548-556. (doi:10.1002/humu.20928)
26. Pęczkowska M, Kowalska A, Sygut J, Waligórski D, Malinoc A, Janaszek-Sitkowska H, Prejbisz A, Januszewicz A & Neumann HP 2013 Testing new susceptibility genes in the cohort of apparently sporadic phaeochromocytoma/paraganglioma patients with clinical characteristics of hereditary syndromes. Clinical Endocrinology 79 817-823. (doi:10.1111/cen.12218)
27. 727 phosphorylation by familial medullary thyroid carcinoma-associated RET mutants induces full activation of STAT3 and is required for c-fos promoter activation, cell mitogenicity, and transformation. Journal of Biological Chemistry 282 6415-6424. (doi:10.1074/jbc.M608952200)
28. Plaza-Menacho I, Barnouin K, Goodman K, Martínez-Torres RJ, Borg A, Murray-Rust J, Mouilleron S, Knowles P & McDonald NQ 2014 Oncogenic RET kinase domain mutations perturb the autophosphorylation trajectory by enhancing substrate presentation in trans. Molecular Cell 53 738-751. (doi:10.1016/j.molcel.2014.01.015)
29. Ren J, Wen L, Gao X, Jin C, Xue Y & Yao X 2009 DOG 1.0: illustrator of protein domain structures. CellResearch 19 271-273. (doi:10.1038/cr.2009.6)
30. Rich TA, Feng L, Busaidy N, Cote GJ, Gagel RF, Hu M, Jimenez C, Lee JE, Perrier N, Sherman SI et al. 2014 Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RETproto-oncogene mutations. Thyroid 24 1096-1106. (doi:10.1089/thy.2013.0620)
31. Rückert F, Görgens H, Richter I, Krex D, Schackert G, Kuhlisch E, Fitze G, Saeger HD, Pilarsky C, Grützmann R et al. 2011 RET-protooncogene variants in patients with sporadic neoplasms of the digestive tract and the central nervous system. International Journal of Colorectal Disease 26 835-840. (doi:10.1007/s00384-011-1150-7)
32. Ruiz-Ferrer M, Fernandez RM, Antinolo G, López-Alonso M, Eng C & Borrego S 2006 A complex additive model of inheritance for Hirschsprung disease is supported by both RET mutations and predisposing RET haplotypes. Genetics in Medicine 8 704-710. (doi:10.1097/01.gim.0000245632.06064.f1)
33. Seri M, Yin L, Barone V, Bolino A, Celli I, Bocciardi R, Pasini B, Ceccherini I, Lerone M, Kristoffersson U et al. 1997 Frequency of RET mutations in long- and short-segment Hirschsprung disease. Human Mutation 9 243-249. (doi:10.1002/(SICI)1098-1004(1997)9:3<243::AID-HUMU5>3.0.CO;2-8)
34. Tamanaha R, Camacho CP, Ikejiri ES, Maciel RM & Cerutti JM 2007 Y791F RET mutation and early onset of medullary thyroid carcinoma in a Brazilian kindred: evaluation of phenotype-modifying effect of germline variants. Clinical Endocrinology 67 806-808. (doi:10.1111/j.1365-2265.2007.02964.x)
35. Toledo SP, dos Santos MA, Toledo RA & Lourenço DM Jr 2006 Impact of RET proto-oncogene analysis on the clinical management of multiple endocrine neoplasia type 2. Clinics (Sao Paulo) 61 59-70. (doi:10.1590/S1807-59322006000100011)
36. Toledo RA, Wagner SM, Coutinho FL, Lourenço DM Jr, Azevedo JA, Longuini VC, Reis MT, Siqueira SA, Lucon AM, Tavares MR et al. 2010 High penetrance of pheochromocytoma associated with the novel C634Y/Y791F double germline mutation in the RET protooncogene. Journal of Clinical Endocrinology and Metabolism 95 1318-1327. (doi:10.1210/jc.2009-1355)
37. Valente FO, Dias da Silva MR, Camacho CP, Kunii IS, Bastos AU, da Fonseca CC, Simião HP, Tamanaha R, Maciel RM & Cerutti JM 2013 Comprehensive analysis of RET gene should be performed in patients with multiple endocrine neoplasia type 2 (MEN 2) syndrome and no apparent genotype-phenotype correlation: an appraisal of p.Y791F and p.C634Y RET mutations in five unrelated Brazilian families. Journal of Endocrinological Investigation 36 975-981. (doi:10.3275/8997)
38. Vestergaard P, Vestergaard EM, Brockstedt H & Christiansen P 2007 Codon Y791F mutations in a large kindred: is prophylactic thyroidectomy always indicated? World Journal of Surgery 31 996-1001. (doi:10.1007/s00268-006-0446-1)
39. Vierhapper H, Rondot S, Schulze E, Wagner L, Hanslik S, Niederle B, Bieglmayer C, Kaserer K & Baumgartner-Parzer S 2005 Primary hyperparathyroidism as the leading symptom in a patient with a Y791F RET mutation. Thyroid 15 1303-1308. (doi:10.1089/thy.2005.15.1303)
40. Virtanen VB, Pukkala E, Kivisaari R, Salo PP, Koivusalo A, Arola J, Miettinen PJ, Rintala RJ, Perola M & Pakarinen MP 2013 Thyroid cancer and co-occurring RET mutations in Hirschsprung disease. Endocrine-Related Cancer 20 595-602. (doi:10.1530/ERC-13-0082)
41. Weber F & Eng C 2005 Editorial: Germline variants within RET: clinical utility or scientific playtoy? Journal of Clinical Endocrinology and Metabolism 90 6334-6336. (doi:10.1210/jc.2005-2030)
42. Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J & Schlumberger M 2010 Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. Journal of Clinical Oncology 28 767-772. (doi:10.1200/JCO.2009.23.6604)